The term cannabinoid refers to pharmacologically active substances originally found within the cannabis plant that led to the discovery of the body’s own cannabinoids, termed endocannabinoids. Endocannabinoids are endogenous neurotransmitters located throughout the brain and peripheral nervous system that are used by certain nerve cells to convey information from cell to cell. The two major endocannabinoid neurotransmitters that have been identified are anandamide (AEA) and 2-arachidonoylglycerol (2-AG), which are secreted and act upon CB1 and CB2 endocannabinoid receptors, thereby influencing a variety of physiological functions, including respiration, appetite, convulsions and potentially others.
Due to the liberalization of state laws regulating the use and sales of cannabis over the last 5 years, a major industry has grown around its commercialization. However, while cannabis use has been legalized in certain states, it still is not legal under federal statutes and regulations. The medical use of any pharmacological agent must be approved by the U.S Food and Drug Administration (“FDA”) and, to date, the FDA has not recognized or approved the cannabis plant as medicine or nutritional supplement nor is it federally legal to sell products that contain cannabinoids as drugs or dietary supplements without its approval.
Worldwide clinical research efforts have established the cannabinoid class of compounds as bona fide pharmaceutical products, or “pharmaceutical cannabinoids,” which are being developed and commercialized according to FDA regulatory and industry guidelines. Scientific research and commercial development to date has focused primarily on two major cannabinoids, dronabinol and cannabidiol (“CBD”). This research and development effort began in 1985 when dronabinol, a directly acting agonist on CB1 and CB2 receptors, was approved by the FDA as Marinol for the treatment of AIDS-related anorexia and later for the treatment of chemotherapy-induced nausea and vomiting.
Delta-9 tetrahydrocannabinol (THC) and CBD are two compounds found in marijuana. These compounds have various effects. THC was the most well-known compound in cannabis until recently. It’s the most active component and has a psychological effect. When smoked or used in cooking, it produces a mind-altering “high.” This is because THC degrades when it is heated and introduced into the body. CBD, on the other hand, is not psychoactive. It does not affect an individual’s mental state when they use it. It may, however, cause significant changes in the body and is showing some note-worthy medical benefits like relieving persistent pain. Several companies tend to provide CBD like ‘getkush’. People can get their hands on it; in case they want some relief from serious medical conditions or severe pain. Kush Oil might even provide oil vaporizer pens and oil cartridges that give fortunate marijuana users a low-key, smooth, and sleek smoking alternative.
This breakthrough subsequently led to the 2018 FDA approval of Epidiolex , a proprietary oral solution of CBD sold by GW Pharmaceuticals plc (“GW Pharma”) for the treatment of certain rare, treatment-resistant forms of epilepsy. On May 5, 2021, GW and Jazz Pharmaceuticals plc (“Jazz”) announced the completion of Jazz’s $7.2 billionacquisition of GW.
The commercialization of these pharmaceutical cannabinoids has opened the door to an expanding market sector. As part of our effort to capitalize upon this opportunity, we have implemented an internal restructuring plan by forming ResolutionRx as a business unit focused on the pharmaceutical cannabinoid market. ResolutionRx’s initial primary focus has been and will continue to be the re-purposing of dronabinol using new proprietary formulations and therapeutic indications. Because dronabinol already is an approved drug, we intend to use publicly available information, particularly safety data, in support of a 505(b)(2) New Drug Application (“NDA”), a potentially more rapid route to FDA approval than a standard 505(b)(1) NDA.